This report contains market size and forecasts of Personal Genome Testing in China, including the following market information:
China Personal Genome Testing Market Revenue, 2016-2021, 2022-2027, ($ millions)
China top five Personal Genome Testing companies in 2020 (%)
The global Personal Genome Testing market size is expected to growth from US$ XX million in 2020 to US$ XX million by 2027; it is expected to grow at a CAGR of XX% during 2021-2027.
The China Personal Genome Testing market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.
QYResearch has surveyed the Personal Genome Testing Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
China Personal Genome Testing Market,
China Personal Genome Testing Market Segment Percentages,
Targeted Testing
Non-Targeted Testing
Multi-Targeted Testing
China Personal Genome Testing Market,
China Personal Genome Testing Market Segment Percentages,
Neurological Disorders
Oncology
Metabolic Disorders
Autoimmune Disorders
Others
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Personal Genome Testing revenues in China market, 2016-2021 (Estimated), ($ millions)
Key companies Personal Genome Testing revenues share in China market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
23andMe, Inc.
Navigenics
deCODEme
Color Genomics, Inc.
Personal Genome Diagnostics, Inc.
Counsyl, Inc.
Quest Diagnostics
Gene By Gene, Ltd.
China Personal Genome Testing Market Revenue, 2016-2021, 2022-2027, ($ millions)
China top five Personal Genome Testing companies in 2020 (%)
The global Personal Genome Testing market size is expected to growth from US$ XX million in 2020 to US$ XX million by 2027; it is expected to grow at a CAGR of XX% during 2021-2027.
The China Personal Genome Testing market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.
QYResearch has surveyed the Personal Genome Testing Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
China Personal Genome Testing Market,
By Type
, 2016-2021, 2022-2027 ($ Millions)China Personal Genome Testing Market Segment Percentages,
By Type
, 2020 (%)Targeted Testing
Non-Targeted Testing
Multi-Targeted Testing
China Personal Genome Testing Market,
By Application
, 2016-2021, 2022-2027 ($ Millions)China Personal Genome Testing Market Segment Percentages,
By Application
, 2020 (%)Neurological Disorders
Oncology
Metabolic Disorders
Autoimmune Disorders
Others
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Personal Genome Testing revenues in China market, 2016-2021 (Estimated), ($ millions)
Key companies Personal Genome Testing revenues share in China market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
23andMe, Inc.
Navigenics
deCODEme
Color Genomics, Inc.
Personal Genome Diagnostics, Inc.
Counsyl, Inc.
Quest Diagnostics
Gene By Gene, Ltd.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.